Search

everythinglearnresearchcommunity

for

Search:↓

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

Addressing hair loss by focusing on posture, blood flow, and craniofacial development. Methods include improving posture, cardiovascular activity, scalp massages, healthy diet, meditation, using minoxidil, and addressing craniofacial issues.

Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.

RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

A new study suggests microneedling alone doesn't benefit male balding, but users argue the study's methods differ from common practices, like combining microneedling with minoxidil and using more frequent treatments. Some believe the study's short duration and infrequent sessions are inadequate to assess microneedling's effectiveness.

A 35-year-old male uses topical minoxidil, spironolactone, and microneedling for hair loss, with spironolactone prescribed based on a DNA test indicating poor response to finasteride and dutasteride. Despite concerns about the test's validity and spironolactone's side effects, he reports stable or improved hair condition and no low testosterone symptoms.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The user experienced significant hair improvement using 1mg finasteride daily without side effects. They are advised to continue treatment to maintain results and consider cost-effective purchasing options.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

A user shared a tragic experience where their cat died after being exposed to Minoxidil, warning others of its toxicity to pets. Some users discussed switching to oral hair loss treatments, while others expressed condolences and shared their own concerns and experiences with topical treatments around pets.

The user is using 5 mg of oral minoxidil, 1.25 mg of finasteride, and a dermaroller for hair loss, and plans to reduce the minoxidil dosage after a year. They have not experienced side effects like facial bloating and are considering the safety of long-term use.

A 27-year-old is experiencing increased hair shedding despite using minoxidil, finasteride, and microneedling. They are concerned about the shedding and seek reassurance and advice from others.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

A user shared impressive hair growth results after 77 days using oral finasteride, topical minoxidil, and weekly microneedling. They reported thicker, darker hair and minimal shedding, with treatment costs around 30 euros per month.

A 16-year-old diagnosed with male pattern baldness (MPB) was prescribed hair vitamins, vitamin D, a non-ketoconazole shampoo, and redenysl + serum, with a suggestion for GFC or IHRF treatments. Some users recommended minoxidil, ketoconazole, and derma stamping, while others advised against certain treatments until the age of 18.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

The user has been using 1mg Finasteride daily for six months, experiencing reduced shedding and itchiness but some frontal thinning. They are considering adding Minoxidil and have started dermarolling to enhance results.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

A new hair growth product claims to use apple stem cells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.

HairClone plans to start hair multiplication services in 2022. Users discuss various treatments like Minoxidil, finasteride, PRP, and hair cloning, expressing both hope and skepticism about the technology and its costs.

A user shared their hair regrowth journey from Norwood 7 at age 22 using oral minoxidil 10mg, dutasteride 0.5mg, and RU58841 70mg, along with a recent hair transplant. They experienced significant progress and discussed potential side effects, particularly with oral minoxidil, and plan to update on further growth.